Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Apr 2024. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
5310133012 | Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
5310134018 | Product containing precisely emtricitabine 200 milligram and rilpivirine (as rilpivirine hydrochloride) 25 milligram and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Plays role | Antiretroviral therapeutic role | false | Inferred relationship | Some | ||
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Emtricitabine (substance) | true | Inferred relationship | Some | 1 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Emtricitabine (substance) | true | Inferred relationship | Some | 1 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Tenofovir disoproxil fumarate (substance) | true | Inferred relationship | Some | 2 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Tenofovir disoproxil (substance) | true | Inferred relationship | Some | 2 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Rilpivirine hydrochloride | true | Inferred relationship | Some | 3 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Rilpivirine | true | Inferred relationship | Some | 3 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 3 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 | |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet | Is a | Product containing only emtricitabine and rilpivirine and tenofovir in oral dose form (medicinal product form) | true | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets